Time-independent maternal and infant factors and time-dependent infant morbidities including HIV infection, contribute to infant growth faltering during the first 2 years of life.
Studies investigating the predictors of growth in infants born to HIV-infected women in developing countries are limited. Using data from 886 Tanzanian HIV-infected women and their infants, we examined the impact of maternal socioeconomic and immunological status, infant characteristics at birth, and HIV, diarrhea and respiratory infections on infants' monthly length-for-age (LAZ) and length-for-weight (WLZ) z-scores during the first 2 years of life. We used restricted cubic splines to estimate average adjusted growth curves by categories of each predictor. LAZ decreased significantly during the first 2 years. WLZ increased from birth to 4 months but decreased significantly thereafter. Greater maternal schooling significantly reduced deterioration in LAZ and WLZ scores from birth to 24 months, while maternal CD4 cell counts >or=200 mm(-3) at baseline were associated with reduced deterioration in LAZ scores. Infants born pre-term or with low-birth weight were significantly more stunted and wasted than their reference groups at all time points though their rate of growth faltering was slower. Infant-HIV status was strongly associated with significantly greater deterioration in LAZ and WLZ scores, beginning at about 4 months of age. Episodes of diarrhea or respiratory infections were related to significantly lower WLZ but not LAZ scores, independent of infant-HIV status. In conclusion, maternal schooling, immunological status and infant infections are important predictors of early growth in children born to HIV-positive women.
Webb
Aimee L
AL
Department of Anthropology, Laboratory for the Study of Constraints on Child Nutrition and Care, University of Toronto, Toronto, ON, Canada.
Manji
Karim
K
Fawzi
Wafaie W
WW
Villamor
Eduardo
E
D002657:Child Development; D002675:Child, Preschool; D015331:Cohort Studies; D003967:Diarrhea / Q000150:complications / Q000453:epidemiology*; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000453:epidemiology* / Q000209:etiology; D015658:HIV Infections / Q000150:complications / Q000453:epidemiology* / Q000635:transmission; D015497:HIV-1; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D008297:Male; D009035:Mothers; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic; D012141:Respiratory Tract Infections / Q000150:complications / Q000453:epidemiology*; D012307:Risk Factors; D012959:Socioeconomic Factors; D013636:Tanzania / Q000453:epidemiology; D013997:Time Factors; D014801:Vitamin A / Q000008:administration & dosage
D014801:Vitamin A